Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
290 DKK | -1.63% | -0.41% | -25.26% |
Apr. 12 | Chemometec A/S Reports Revenue for the Third Quarter and First Nine Months of 2023 -2024 | CI |
Apr. 12 | ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.31 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.26% | 735M | D | ||
+73.54% | 12.37B | B- | ||
-18.54% | 7.96B | C+ | ||
+15.29% | 7.09B | C- | ||
+3.39% | 5.83B | B | ||
+11.77% | 5.35B | D+ | ||
+29.65% | 4.63B | - | ||
-17.74% | 4B | B- | ||
-34.95% | 2.41B | C | ||
+2.10% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHEMM Stock
- Ratings ChemoMetec A/S